Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04033354
Title A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Shanghai Henlius Biotech
Indications

lung squamous cell carcinoma

Therapies

Carboplatin + Nab-paclitaxel + Serplulimab

Carboplatin + Nab-paclitaxel

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST